The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2025 | The current and future treatment paradigm of ALK rearranged NSCLC
Jay Lee, MD, University of California, Los Angeles, CA, provides an overview the current state of ALK TKI-directed therapies in the early-stage non-small cell lung cancer (NSCLC), highlighting the need for further development in later generations of TKIs. Dr Lee comments on the safety profile and efficacy of second-generation ALK TKIs, including pathologic regression and radiographic response rates from Phase II clinical trials, as well as some studies with first-generation crizotinib. This interview took place at 2025 World Conference on Lung Cancer (WCLC) in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So the educational talk is really to provide an overview of ALK TKI-directed therapies in the early-stage setting. There are four generations of ALK TKIs and much of the research currently is on the second-generation ALK TKIs. There are only two phase 2 studies looking at third-generation lorlatinib in the adjuvant setting. There are no neoadjuvant phase 3 trials with third-generation or fourth-generation drugs...
So the educational talk is really to provide an overview of ALK TKI-directed therapies in the early-stage setting. There are four generations of ALK TKIs and much of the research currently is on the second-generation ALK TKIs. There are only two phase 2 studies looking at third-generation lorlatinib in the adjuvant setting. There are no neoadjuvant phase 3 trials with third-generation or fourth-generation drugs. So this is an area of development in the later TKIs that we need to do. So I provide an overview of the safety profile and the efficacy, both the pathologic regression as well as the radiographic response rates that we would expect from the five phase 2 clinical trials with mainly second-generation ALK TKIs, and there are some studies with first-generation crizotinib.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
